Company / Operating Income
Edesa Biotech, Inc. Operating Income History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$6.4M
FY2021
5-year range
-$6.4M / -$2.8M
FY2017-FY2021
Trend
-126.0%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 5 years, ranging from -$6M in FY2021 to -$3M in FY2020.
Based on SEC 10-K filings.
-$6M in FY2021.
Declined from -$5M to -$6M over the past 3 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, operating income decreased 126.0% year-over-year.
- Peak operating income was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | -$6.4M | -126.0% |
| FY2020 | -$2.8M | +45.8% |
| FY2018 | -$5.2M | -20.4% |
| FY2017 | -$4.3M | +24.1% |
| FY2016 | -$5.7M | - |
| FY2015 | - | - |
| FY2014 | - | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026